TFX

In a comparison of two Medical Instruments stocks, Teleflex (TFX) emerges as the better value opportunity compared to SONOVA HOLDING (SONVY). TFX has a superior Zacks Rank of #2 (Buy) versus SONVY's #3 (Hold), along with more attractive valuation metrics including a lower forward P/E ratio of 17.36 versus 21.87, a PEG ratio of 0.84 versus 2.42, and a P/B ratio of 1.91 versus 5.51. TFX earned a Value grade of B while SONVY received a D grade.

Teleflex (TFX) reported Q2 2026 Vascular revenue growth of 9% driven by central access and hemostatic product demand, with Asia revenues jumping 59.5%. However, tariffs and acquisition costs pressured margins, with adjusted operating margin declining 520 basis points. The company improved its balance sheet with pro forma net leverage at 1.9X after debt repayment.